Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

TMCI earnings analysis

Filed May 8, 2026 · Our reading of the company's report

The latest report

Treace Medical Concepts reported a decrease in Q1 2026 revenue to $47.2 million, missing estimates of $46.0 million, along with a wider net loss of $(18.0) million, or EPS of $(0.28). The company continues to face…

Read full summary

Treace Medical Concepts reported a decrease in Q1 2026 revenue to $47.2 million, missing estimates of $46.0 million, along with a wider net loss of $(18.0) million, or EPS of $(0.28). The company continues to face operational challenges, maintaining full-year revenue guidance of $202 million to $212 million amid a competitive and challenging economic environment.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.28
Gross margin
79.3%

What stood out

  • Q1 Revenue Decline

    Revenue fell 10.2% YoY to $47.2M from $52.6M in Q1 2025.

  • Wider Net Loss

    Net loss increased to $(18.0) million or $(0.28) EPS, compared to $(15.9) million in Q1 2025.

  • Gross Margin Slightly Declined

    Gross margin for the quarter decreased to 79.3%, down from 79.7% a year ago.

  • Decrease in Operating Expenses

    Total operating expenses decreased 5.0% to $54.6 million from $57.5 million in Q1 2025.

  • Strong Cash Flow from Operations

    Operating cash flow increased to $7.2 million from $4.2 million in Q1 2025.

  • Stable Cash Position

    Cash and cash equivalents at $9.5 million plus $42.3 million in marketable securities.

What to watch

  • Increased Competition

    Increased competition from various companies has eroded market share, as seen with lower sales of the flagship Lapiplasty System.

  • Macroeconomic Headwinds

    Ongoing macroeconomic challenges, including inflation and consumer confidence, are anticipated to continue affecting demand for elective surgeries.

  • Legal Challenges

    Multiple ongoing lawsuits, including those against Stryker and Zimmer, could have indefinite impacts on finances and operations.

Management's outlook

Full-year 2026 revenue guidance remains at $202 million to $212 million, reflecting expected case volume growth amid product mix headwinds.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.